These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 10616557

  • 1. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B.
    Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract] [Full Text] [Related]

  • 2. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F.
    Transplant Proc; 2001 Dec; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract] [Full Text] [Related]

  • 3. Immunosuppressive [correction of immunosupressive] agents and their actions.
    First MR.
    Transplant Proc; 2002 Aug; 34(5):1369-71. PubMed ID: 12176401
    [No Abstract] [Full Text] [Related]

  • 4. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Spasovski G, Sikole A, Paneva-Masin J.
    Transplant Proc; 2001 Aug; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract] [Full Text] [Related]

  • 5. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L, Henriques AC, Dias L, Sarmento AM, Pereira MC, Guimarães S.
    Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract] [Full Text] [Related]

  • 6. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 7. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Apr 27; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 8. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J, Marcén R, Ortuño J.
    Nephrol Dial Transplant; 2001 Sep 27; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract] [Full Text] [Related]

  • 9. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
    Vincenti F, Nashan B, Light S.
    Transplant Proc; 1998 Aug 27; 30(5):2155-8. PubMed ID: 9723424
    [No Abstract] [Full Text] [Related]

  • 10. Daclizumab.
    Mottershead M, Neuberger J.
    Expert Opin Biol Ther; 2007 Oct 27; 7(10):1583-96. PubMed ID: 17916050
    [Abstract] [Full Text] [Related]

  • 11. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP, Nampoory MR, Johny KV, Costandi JN, Abdulhalim M, El-Reshaid W, Al-Muzairai I, Ninan VT, Samhan M, Al-Mousawi M.
    Transplant Proc; 2001 Aug 27; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
    Abou-Jaoude MM, Ghantous I, Almawi WY.
    Mol Immunol; 2003 Jul 27; 39(17-18):1083-8. PubMed ID: 12835081
    [Abstract] [Full Text] [Related]

  • 13. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L, Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA.
    Cochrane Database Syst Rev; 2013 Dec 02; (12):CD008842. PubMed ID: 24297433
    [Abstract] [Full Text] [Related]

  • 14. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
    Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber AO.
    Transplant Proc; 2001 Dec 02; 33(1-2):1701-3. PubMed ID: 11267477
    [No Abstract] [Full Text] [Related]

  • 15. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J.
    N Engl J Med; 1998 Jan 15; 338(3):161-5. PubMed ID: 9428817
    [Abstract] [Full Text] [Related]

  • 16. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F, Humeres R, Zamboni M, Sanhueza E, Zapata R, Hepp J, Rius M.
    Transplant Proc; 2003 Nov 15; 35(7):2520-1. PubMed ID: 14612001
    [Abstract] [Full Text] [Related]

  • 17. Daclizumab: a potential asthma therapy?
    Antoniu SA.
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov 15; 4(3):214-21. PubMed ID: 20804450
    [Abstract] [Full Text] [Related]

  • 18. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F.
    Transplant Proc; 1999 Sep 15; 31(6):2206-7. PubMed ID: 10500546
    [No Abstract] [Full Text] [Related]

  • 19. New immunosuppressive agents in pediatric renal transplantation.
    Ettenger RB.
    Transplant Proc; 1998 Aug 15; 30(5):1956-8. PubMed ID: 9723350
    [No Abstract] [Full Text] [Related]

  • 20. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.
    van de Linde P, Vd Boog PJ, Tysma OM, Elliott JF, Roelen DL, Claas FH, de Fijter JW, Roep BO.
    Clin Exp Immunol; 2007 Jul 15; 149(1):56-62. PubMed ID: 17459076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.